Chipotle Mexican Grill is set to report its latest quarterly results Tuesday afternoon, with investors watching closely for signs of resilience in consumer spending and operational execution against a backdrop of moderating sales growth.
As SpaceX reportedly engages banks for a potential 2026 public offering, the pre-IPO secondary market for late-stage tech giants is booming, offering a critical liquidity valve and reshaping the path to going public.
As SpaceX targets a record-shattering IPO for mid-2026, reports indicate Elon Musk is exploring a potential merger with either Tesla or his AI startup, xAI. The move could create a unified tech and industrial behemoth but faces significant regulatory and operational hurdles.
Klarna Group faces a dual challenge: surging commercial demand for its 'buy now, pay later' services and intensifying legal scrutiny over alleged IPO disclosure failures regarding credit risk. The stock's sharp decline shifts investor focus to upcoming quarterly results and credit quality metrics.
Robinhood Markets is making a bold two-pronged move, expanding its tokenized stock offerings while positioning itself as a key retail gateway for SpaceX's anticipated IPO. This strategy underscores its ambition to democratize high-profile investments but also intensifies scrutiny on its regulatory risks and valuation.
Klarna Group confronts a wave of class action lawsuits alleging it downplayed rising loan loss risks in its buy-now-pay-later portfolio ahead of its 2025 NYSE debut. The legal challenges cast a shadow over the fintech's post-IPO performance and have sparked a broader debate about transparency in the rapidly growing BNPL sector.
After a volatile debut, Figma's stock presents a classic growth investing dilemma. Bulls point to its rapid user adoption and potential to reshape digital design, while its lofty valuation demands flawless execution in a competitive market.
The new year kicked off with significant personnel changes in the human resources executive suite, highlighting strategic expansions of roles and notable returns to former companies.
Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Indian e-commerce challenger Meesho reported a significant widening of its quarterly net loss to ₹4.91 billion, as a 44% surge in expenses outpaced strong revenue growth, marking a costly start to its life as a public company.
Defense contractor L3Harris Technologies capped off a record 2025 with surging orders and a strategic pivot, announcing plans to take its high-growth Missile Solutions unit public in 2026 while securing a novel $1 billion investment from the Department of War to accelerate production.
Elon Musk is reportedly exploring a major consolidation of his business empire, with SpaceX considering mergers either with electric vehicle giant Tesla or his artificial intelligence startup xAI, as the space company prepares for a landmark public offering.
SpaceX is reportedly targeting June 2026 for its long-awaited public market debut, with sources suggesting the timing could be synchronized with a rare planetary alignment and CEO Elon Musk's 55th birthday, as the company seeks capital for its ambitious Mars missions.
HSBC Holdings is aggressively rebuilding its investment banking operations in Hong Kong and key Asian hubs, reallocating senior talent and capital to capture growth in IPOs and capital markets, as its strategic focus shifts decisively eastward.
From post-IPO darling to a stock trading near historic lows, Rivian faces a critical five-year window. With new models on the horizon and a major Volkswagen partnership, analysts see a path to growth—if it can navigate fierce competition and persistent losses.
Insulet (PODD) shares have faced significant pressure in recent months, diverging from the company's underlying business performance. This analysis delves into whether the current price weakness presents a buying opportunity for the Omnipod maker or reflects deeper market concerns about its premium valuation and growth sustainability.
Shares of diabetes care innovator Insulet have tumbled nearly 10% year-to-date, sparking a fierce debate among investors. While a key valuation model suggests the stock is deeply undervalued, its sky-high P/E ratio tells a conflicting story. We examine the numbers and what they mean for the future of the Omnipod maker.
Elon Musk is reportedly in early-stage talks to merge his flagship companies—SpaceX, Tesla, and xAI—into a single, trillion-dollar technology and infrastructure behemoth ahead of a potential SpaceX IPO, sources familiar with the matter indicate.
As OpenAI accelerates toward a potential year-end IPO, Amazon, Microsoft, and Nvidia are in advanced talks to lead a funding round that could exceed $100 billion, reshaping the AI industry's financial and competitive landscape.
